AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05710068
Drug: Combination cream
RxNorm normalized name: SUNSCREEN-35 PABA-FREE COMBINATION CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
Trial: NCT05149274
Drug: DWP14012 Tablet A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 10mg
Trial: NCT05149274
Drug: DWP14012 Tablet B
RxNorm normalized name: ACTION B-100 TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 40mg
Trial: NCT05556863
Drug: ELA026
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ELA026
Trial: NCT05556863
Drug: ELA026
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of ELA026
Trial: NCT05051566
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04829344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Ophthalmic Solution
Trial: NCT04106999
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline will be infused as a control drug
Trial: NCT06130059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05997043
Drug: oral anti-Parkinson's drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group only took oral anti-Parkinson's drugs.
Trial: NCT05605119
Drug: AUR105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT04826354
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin
Trial: NCT06293729
Drug: NGGT006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).
Trial: NCT05566652
Drug: Pressure Support Ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
Trial: NCT05909332
Drug: Antivascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP102 (anti VEGFR)
Trial: NCT05909332
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddEC-P
Trial: NCT05748405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Tablets
Trial: NCT05748405
Drug: AEF0217
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of 100 mcg AEF0217
Trial: NCT06578234
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard dose 140 μg/kg/min and high dose 210 μg/kg/min adenosine
Trial: NCT03782155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: powder 17g
Trial: NCT06305351
Drug: K-757 and K-833 QD
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both administered orally once daily
Trial: NCT06305351
Drug: K-757 and K-833 BID
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both administered orally twice daily
Trial: NCT06305351
Drug: Matching placebo to K-757 and K-833 QD
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both administered orally once daily
Trial: NCT06305351
Drug: Matching placebo to K-757 and K-833 BID
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both administered orally twice daily
Trial: NCT05780645
Drug: ALXN2050 Immediate Release (IR) Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
Trial: NCT05780645
Drug: ALXN2050 MR Prototype Mini-Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive various doses of the MR Prototype Mini-Tablet orally.
Trial: NCT04298567
Drug: Acetylsalicylic acid(ASA)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA (75mg \[QD\]; dose according to local label.
Trial: NCT06607276
Drug: Adebrelimab and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adebrelimab: 1200mg, IV, q3w for one year; capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
Trial: NCT06607276
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
Trial: NCT05465226
Drug: Historical opioid use
RxNorm normalized name: Drugs used in opioid dependence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical matched, control group in 2:1 ratio
Trial: NCT06342596
Drug: [14C]-LY3473329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06342596
Drug: [14C]-LY3473329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT06342596
Drug: LY3473329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04717193
Drug: Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
Trial: NCT05318105
Drug: IV Loop Diuretics
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diuretics
Trial: NCT05151679
Drug: Chelated Iron
RxNorm normalized name: Chelated Iron 15 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be started 24rh after initial visit women will be randomized used random sequence computer generated list in such a way that every patient had equal chance to be among any of the two groups either to group 1 , where they will receive I.V ferrous sucrose in the E.U in Women's Health Hospital Assuit University as an i.v infusion in 250 ml 0.9% sodium chloride slowly over 30 minutes.~The total required dose of iron will be divided into three doses, which will be given every 3 days, and the maximum daily dose is 200mg ( 2 ampoules ).
Trial: NCT05010148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D5 water given at an equivalent ml/hr as intravenous lidocaine (treatment arm) for 48 hours following major spinal surgery
Trial: NCT03734731
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
Trial: NCT06344312
Drug: Yangxue Qingnao Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
Trial: NCT05378945
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
Trial: NCT05427669
Drug: mFOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
Trial: NCT05427669
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
Trial: NCT06490484
Drug: HSK16149 20mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.
Trial: NCT06732245
Drug: NA-931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (Zepbound) placebo
Trial: NCT04656847
Drug: in daily everyday routine practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.
Trial: NCT06732245
Drug: NA-931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA-931, an oral, daily~• A quadruple receptor agonist
Trial: NCT06732245
Drug: NA-931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound
Trial: NCT06732245
Drug: NA-931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA-931 (oral daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound
Trial: NCT04899518
Drug: ALY688 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT06174363
Drug: Maxigesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
Trial: NCT06174363
Drug: 0.9% saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
Trial: NCT01947608
Drug: LDK378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg. orally
Trial: NCT05086289
Drug: LY3526318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05086289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04982900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo has the same appearance, weight, and physical and chemical properties as the study drug, and is provided by the researcher to the subjects in control group.
Trial: NCT06669299
Drug: Antiarrhythmic Drug Therapy (amiodarone, sotalol, or mexiletine)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients with a positive NIPS already on antiarrhythmic drugs (AAD) before the index procedure will re-start the original antiarrhythmic therapy. Patients who were not on AAD will start a new drug at the operator's discretion (amiodarone, sotalol, or mexiletine) according to clinical practice.
Trial: NCT06740240
Drug: 68Ga-FAPI-Biotin
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer doses of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT
Trial: NCT06669429
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
Trial: NCT06669429
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
Trial: NCT06669429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast
Trial: NCT06669403
Drug: OPT101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
Trial: NCT06224881
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 gm every 8hrs for 4 days
Trial: NCT06670352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD or BID, 24-weeks fixed dose.
Trial: NCT06670352
Drug: HSK39297 50mgBID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-weeks fixed dose.
Trial: NCT06670352
Drug: HSK39297 100mgBID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-weeks fixed dose.
Trial: NCT06670352
Drug: HSK39297 200mgQD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-weeks fixed dose.
Trial: NCT06241755
Drug: BCG for Therapeutic Use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.
Trial: NCT06241755
Drug: BCG for Therapeutic Use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.
Trial: NCT06080776
Drug: Placebo SH-1028 tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SH-1028 tablets.
Trial: NCT05321498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be delivered by subcutaneous injection once a week
Trial: NCT06192680
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² PO BID
Trial: NCT06017583
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
Trial: NCT06191887
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05140954
Drug: co-formulated 25mg TAF/ 200mg FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
Trial: NCT05394740
Drug: CapeOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Cohort A only~* Capecitabine 1,000 mg/m\^2 administered orally, twice daily (Days 1 to 14 continuous dosing of CapeOX therapy)~* Oxaliplatin 130 mg/m\^2 administered intravenously (Day 1 of CapeOX therapy) \*Repeat every 3 weeks as CapeOX therapy
Trial: NCT05394740
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Cohort B only~* Leucovorin 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy)~* Fluorouracil 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)~* Oxaliplatin 85 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) \*Repeat every 2 weeks as FOLFOX therapy
Trial: NCT06166914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
Trial: NCT05582265
Drug: Carboplatin (neoadjuvant）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT05582265
Drug: Carboplatin (adjuvant）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT05981768
Drug: Cytisinicline
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Trial: NCT05763160
Drug: RZL-012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready to use drug product for injection into the subcutaneous fat
Trial: NCT05491694
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/m2，IVD，q3w
Trial: NCT05244473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT05298696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT05403580
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03911336
Drug: Group A - test:Tooth extraction and intake of NSAID and a non-NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
Trial: NCT03911336
Drug: Group C - Control 2: tooth extraction and intake of a Non-Nsaid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
Trial: NCT04811469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution, given once
Trial: NCT06214572
Drug: Systemic therapy (Gemcitabine plus Cisplatin)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one of the following Gemcitabine-based systemic therapy alone:~Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~Duration: 3 months (in addition to 3 months previously received)
Trial: NCT06214572
Drug: Systemic therapy (Gemcitabine plus oxaliplatin)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~Duration: 3 months
Trial: NCT06214572
Drug: Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~Duration 3 months Durvalumab (12 months)
Trial: NCT06214572
Drug: Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w Duration: 3 months
Trial: NCT05003531
Drug: IBI112 dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo or dose 2 IBI112 SC
Trial: NCT05003531
Drug: IBI112 dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo or dose 4 IBI112 SC
Trial: NCT05003531
Drug: IBI112 dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo or dose 1 IBI112 SC
Trial: NCT05003531
Drug: IBI112 dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo or dose 3 IBI112 SC
Trial: NCT05003531
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo SC
Trial: NCT05277688
Drug: adjuvant concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
Trial: NCT05314439
Drug: ION904
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ION904 will be administered by SC injection.
Trial: NCT05314439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by SC injection.
Trial: NCT05429229
Drug: Humylub PF®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
Trial: NCT05317364
Drug: Placebo vaginal cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream